Douglas C. Throckmorton, M.D. Deputy Director for Regulatory Programs Center for Drug Evaluation and Research at the FDA delivered the following statement on June 14 to Congress:
“Combating opioid misuse, abuse, and addiction has long been a priority for the Agency, and FDA has taken many steps to address this problem over the last few decades. We have taken action to build upon existing initiatives and develop new ones, including establishing a task force to focus on this critical issue.
Over the last decade or so, FDA has worked to pursue a targeted, science-based, multi-pronged approach that addresses misuse, abuse, and addiction at critical points in the development of an opioid product and in its use throughout the health care system. This comprehensive approach includes five broad areas:
- Encouraging scientific work into the development of safe and effective treatments for pain and into the most appropriate uses of pain medicines;
- Encouraging the development of abuse-deterrent drug formulations for opioids;
- Working to improve the appropriate use of opioids to treat pain through prescriber and patient education;
- Evaluating opioid labeling, and
- Improving the availability of products that treat abuse and overdose.
The statement can be accessed at: http://www.fda.gov/NewsEvents/Testimony/ucm356674.htm
Source: Federal Drug Administration – June 14, 2013